Oncology Corporate Profile
Annias Immunotherapeutics, Inc. is a clinical stage immuno-oncology company focused on the development of novel immunotherapeutic approaches to the treatment of cancers that containing Cytomegalovirus (CMV). The company’s approach is based on a patented and proprietary immunotherapeutic platform, discovered at Duke University, which harnesses the body’s immune system to recognize, attack and destroy tumor cells containing CMV. CMV is over-expressed in a variety of human cancers including significant and homogeneous expression in almost all glioblastoma, but not in normal brain tissue.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|PEPIDH1M||dendritic cell vaccine||Glioblastoma Multiforme (GBM)||I|